Drug intelligence / Profile preview

EVE132

Development stage: Preclinical
Lead developer: Evestra
Modality: Small Molecules

Overview

EVE132 is a chemical drug candidate developed by Evestra for the treatment of uterine fibroids, with additional potential in neoplasms and urogenital diseases. As of May 2025, it remains in preclinical development. Specific details regarding its mechanism of action, molecular target(s), or pharmacological class have not been disclosed publicly. The drug is being advanced by Evestra, a company focused on women's health and gynecological disorders[1].

Beyond the preview

Go deeper on EVE132.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVE132.

Explore the full profile